Urolithin A gets the headlines, the clinical trials and the supplement-shelf space. But a new paper puts its lesser-known sibling, urolithin D, in the spotlight. In aging mice, it was linked to better memory, less hippocampal damage and a boost to the cell's mitochondrial quality-control machinery.
Before anyone adds it to a cart: this is a mouse study with cell experiments. There is no human data, and urolithin D is not a common supplement.
The Study at a Glance
The work was published as Chen P, Wang Y, Huang Y, et al., "Ellagitannin Metabolite Urolithin D Ameliorates Cognitive Function and Behavioral Performance in Aging Mice Partially via AMPK/PGC-1α/SIRT3-Dependent Regulation of Mitophagy-Related Molecular Machinery," Molecular Neurobiology, 2026;63(1):952. DOI: 10://doi.org/10.1007/s12035-026-06245-5. PubMed: 42842065.
The team, from hospitals and a pharmaceutical sciences school in Wuhan, China, tested urolithin D in two settings:
- Mice: Animals received daily intraperitoneal injections of 150 mg/kg D-galactose for 8 weeks. They also received urolithin D by oral gavage at 50–150 mg/kg/day.
- Cells: HT22 neuronal cells (a mouse hippocampal cell line) were stressed with D-galactose to see what urolithin D did to mitochondria and related proteins.
Why the Model Matters
The "aging" in these mice is not natural aging. D-galactose is injected at high doses to chemically induce aging-like changes, a common shortcut in the lab. It is useful for screening compounds, but it is not the same as a mouse (or a person) growing old over years. Any claim about "reversing aging" would be a stretch.
What Urolithin D Did
Per the abstract, urolithin D treatment in the D-galactose mice:
- Improved cognitive performance and behavioral impairment
- Reduced hippocampal pathology (the hippocampus is a key memory region)
- Preserved synaptic plasticity
- Alleviated aging symptoms
The abstract does not give effect sizes in the text, so "improved" here means what the authors report qualitatively. It does not mean memory was fully restored.
The Mechanism: Mitochondrial Housekeeping
The authors tie the effects to mitophagy, the process cells use to clear out damaged mitochondria. They report that urolithin D:
- Raised levels of AMPK, PGC-1α and mitochondrial SIRT3, three proteins tied to energy sensing and mitochondrial function
- Shifted mitophagy-associated signaling, with altered expression of Beclin1, LC3, P62, Parkin and PINK1
- In stressed neuronal cells, helped normalize mitochondrial shape, oxidative stress and calcium homeostasis
The cell experiments probed causality. Knocking down SIRT3 in HT22 cells increased mitochondrial damage and suppressed mitophagy-related machinery. Inhibiting AMPK or PGC-1α abolished urolithin D's protective effects, while overexpressing SIRT3 eased the D-galactose-induced abnormalities.
The authors say urolithin D "partially" triggers changes consistent with mitophagy activation through this AMPK/PGC-1α/SIRT3 cascade. "Partially" matters: it is one pathway among likely several.
Urolithin D vs. Urolithin A: What We Can and Can't Say
The paper does not compare urolithin D with urolithin A. Nobody has shown here that D beats A, matches A, or even works through a different route. The framing is simply that both belong to the same family of gut-derived metabolites, and that urolithin A, the better-known one, has human supplement products, while urolithin D largely sits in the research literature.
What the new work adds is a signal that other urolithins may also touch the mitophagy-AMPK-SIRT3 axis in brain cells.
Where Urolithins Come From
Urolithins are not in food directly. Ellagitannins and ellagic acid, found in pomegranate and walnuts (and also in some berries), are converted by gut bacteria into urolithins. That has two implications:
- People differ in which urolithins their microbiome produces, and how much.
- Eating ellagitannin-rich foods is not the same as taking a purified compound at the doses used in the mice.
Practical Takeaways
Dose: There is no human dose for urolithin D. The 50–150 mg/kg/day in mice is a laboratory dose and cannot be converted into a safe or effective human amount from this study.
Timing: The mice were treated daily for 8 weeks alongside D-galactose. That is a prevention-style design, not evidence about treating existing memory problems, and it says nothing about the best time of day.
Who it might be relevant for: Today, mostly researchers. For general readers, the relevant action is eating ellagitannin-containing foods like pomegranate and walnuts, or looking at urolithin A products, which do exist commercially. Check the evidence and quality for any specific product yourself.
Who should skip it: Anyone hoping to self-treat memory loss or neurodegeneration with this compound. Also be cautious if you are pregnant, take medications, or have a medical condition; talk to a clinician before taking concentrated supplements. Safety of urolithin D in humans has not been assessed in this work.
What to Watch For
- Human trials: None exist for urolithin D in this paper. Look for pharmacokinetic and safety data first.
- Head-to-head studies: A direct comparison with urolithin A would show whether D offers anything distinct.
- Natural-aging models: Results in chemically induced aging need confirming in naturally aged animals.
- Brain exposure: The study doesn't establish how much urolithin D reaches the human brain after oral intake.
Bottom Line
Urolithin D is an intriguing, early-stage lead: in a D-galactose mouse model and neuronal cells, it improved memory-related outcomes through a pathway involving AMPK, PGC-1α, SIRT3 and mitophagy. It is not a proven human memory aid, and it is not a supplement you can reasonably evaluate yet. The authors declared no competing interests, and the animal work had institutional ethics approval.